The 20 most recent market catalysts affecting $ALAB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 85
Why Is Astera Labs Stock Surging Monday?
Astera Labs (ALAB) experienced a significant stock surge due to an upgrade from Northland Capital Markets, moving its rating from Market Perform to Outperform and setting a $350 pr…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 75
Astera Labs shares are trading higher after Northland Capital Markets upgraded its rating on the stock from Market Perform to Outperform and announced a $350 price target.
The upgrade from Market Perform to Outperform by Northland Capital Markets, coupled with a $350 price target, is a strong positive signal for Astera Labs. This suggests that the an…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 75
Northland Capital Markets Upgrades Astera Labs to Outperform, Announces $350 Price Target
Northland Capital Markets analyst Gus Richard upgraded Astera Labs (ALAB) from Market Perform to Outperform and announced a $350 price target. This is a significant positive develo…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
Morgan Stanley Maintains Overweight on Astera Labs, Raises Price Target to $382
Morgan Stanley analyst Joseph Moore has raised the price target for Astera Labs (ALAB) from $335 to $382, while maintaining an 'Overweight' rating. This action signals a strong vot…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Astera Labs, Raises Price Target to $500
RBC Capital's analyst Srini Pajjuri has maintained an 'Outperform' rating on Astera Labs (ALAB) and raised the price target from $425 to $500. This action signals strong analyst co…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
Astera Labs shares are trading lower despite reporting better-than-expected Q2 financial results and issuing Q3 adjusted EPS and sales guidance above estimates. The stock may be experiencing some profit taking after rising roughly 250% since early April.
The headline indicates a classic 'sell the news' scenario, where a stock's impressive run-up leads investors to take profits even on positive fundamental announcements. This is a c…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
Evercore ISI Group Maintains Outperform on Astera Labs, Raises Price Target to $452
Evercore ISI Group analyst Mark Lipacis has maintained an 'Outperform' rating on Astera Labs and raised the price target from $297 to $452. This significant increase in the price t…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
Astera Labs Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Earnings
Astera Labs (ALAB) announced Q2 2026 results that significantly surpassed analyst expectations for both earnings and revenue, driven by strong performance across its product portfo…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
Needham Maintains Buy on Astera Labs, Raises Price Target to $425
Needham analyst N. Quinn Bolton has maintained a 'Buy' rating for Astera Labs and substantially raised the price target from $260 to $425. This move indicates a strong belief in th…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
Jefferies Maintains Buy on Astera Labs, Raises Price Target to $450
Jefferies analyst Blayne Curtis has maintained a 'Buy' rating on Astera Labs (ALAB) and substantially raised the price target from $270 to $450. This significant increase in the pr…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 95
Astera Labs shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 guidance above estimates.
This headline represents a major corporate catalyst for Astera Labs, directly impacting its stock price positively due to exceeding financial expectations. The strong performance a…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 95
Astera Labs Stock Shoots Higher After Q2 Earnings — Here's Why
Astera Labs (ALAB) announced exceptional Q2 2026 financial results, surpassing analyst expectations for both EPS and revenue. The company's revenue growth of 104% year-over-year an…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 95
Astera Labs Sees Q3 Adj EPS $1.16-$1.21 vs $0.81 Est; Sees Sales $540.000M-$560.000M vs $416.526M Est
Astera Labs (ALAB) released Q3 guidance that projects adjusted EPS of $1.16-$1.21, significantly higher than the analyst estimate of $0.81. Similarly, sales are expected to be $540…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
Astera Labs Q2 Adj. EPS $0.80 Beats $0.69 Estimate, Sales $392.400M Beat $360.724M Estimate
Astera Labs' significant beat on both EPS and sales is a strong positive signal for the company and the broader semiconductor industry, especially those focused on data center and …
Jul 30, 2026
Corporate Catalyst
Neutral
Impact 55
Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stock
The filing primarily conveys Jim Cramer's stock recommendations and opinions. His 'buy' call on Astera Labs (ALAB) ahead of its Q2 earnings could generate short-term positive senti…
Jul 28, 2026
Market Technicals
Bearish
Impact 65
Astera Labs Stock Is Falling Tuesday: What's Going On?
Astera Labs (ALAB) stock fell nearly 8% on Tuesday, primarily due to investors trimming exposure to high-beta AI infrastructure stocks before its earnings report next week. This de…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 65
Why Is Astera Labs Stock Falling on Thursday?
Astera Labs (ALAB) stock is falling due to a confluence of factors: profit-taking after recent gains, substantial insider selling by Board Chairman Manuel Alba and Director Stefan …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
Why Is Astera Labs Stock Surging Tuesday?
Astera Labs (ALAB) stock experienced a significant surge, rebounding from a prior session's pullback, primarily due to TD Cowen raising its price forecast to $425 while keeping a '…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.